Direxion Daily S&P 500 Bear 3X (ARCA: SPXS)

Ultime notizie per Direxion Daily S&P 500 Bear 3X (ARCA:SPXS)

Direxion Daily S&P 500 Bear 3X

Direxion

The fund, under normal circumstances, invests at least 80% of its net assets (plus borrowing for investment purposes) in swap agreements, futures contracts, short positions or other financial instruments that provide inverse (opposite) or short daily exposure to the index or to ETFs that track the index, which, in combination, provider returns consistent with the fund’s investment objective. The index is a float-adjusted, market capitalization-weighted index. The fund is non-diversified.

Dreyfus Govt Cash Man Ins

Gs Financial Square Treasury Instruments Fund

Goldman Sachs Fin Gov 465 Institut

Dreyfus Trsy Prime Cash Mgmt - In 0 -

Direxion Daily S&P 500 Bear 3X Shares

Spirax Group PLC

SPIRAX GROUP PLC UNSP/ADR by SPIRAX GROUP PLC

On Friday, April 11, 2025, Cathie Wood-led Ark Invest executed notable trades, shedding shares in UiPath Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>), Prime Medicine Inc. (NGM: PRME), and Repare Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>).
The PATH Trade
Ark Invest&#8217;s ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) fund sold 4,256 shares of UiPath Inc. Based on the closing price of $10.87 on the day of the trade, the total value of the transaction amounts to approximately $46,280.32.
UiPath&#8217;s stock saw a slight increase of 2.26% on the day.
The PRME Trade
Prime Medicine Inc. was another company that Ark Invest decided to reduce its stake in. The ARKK fund sold 83,510 shares of PRME. With the stock closing at $1.33 on the day of the trade, the value of the sold shares is around $111,068.30.
Interestingly, PRME&#8217;s stock experienced a significant surge of 13.68% on the trade day.
See Also:<a href="https://www.benzinga.com/news/management/25/04/44774273/jpmorgan-ceo-jamie-dimon-expects-sp-500-growth-forecast-to-be-cut"> JPMorgan CEO Jamie Dimon Expects S&amp;P 500 Growth Forecast To Be Cut</a>
The RPTX Trade
Ark Invest&#8217;s Ark Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>) fund offloaded shares of Repare Therapeutics Inc. The fund sold 130,611 shares of RPTX. Given the closing price of $0.9 on the trade day, the total value of the transaction is approximately $117,549.90. The stock&#8217;s price remained unchanged on the day of the trade.
These trades come in the wake of <a href="https://www.benzinga.com/25/04/44753971/cathie-woods-thursday-plays-healthcare-ai-and-crypto-ark-scoops-up-tempus-ai-and-coinbase-stock-amid-trump-tariff-crash">Ark Invest&#8217;s previous transactions</a>, which featured prominent purchases of Tempus AI Inc and Coinbase Global Inc stocks amid a sharp market selloff triggered by economic uncertainty and a 145% China tariff announcement by the Trump administration.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/personal-finance/25/04/44774554/analyst-says-recession-chance-higher-than-50-musks-doge-cuts-to-knock-out-gdp-were-getting-closer-to-recession">Analyst Says Recession Chance Higher Than 50%, Musk&#8217;s DOGE Cuts to &#8216;Knock Out&#8217; GDP — &#8216;We&#8217;re &#8216;Getting Closer to Recession&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Equities

News

Markets

ARKG

ARKK

PATH

PRME

RPTX

Cathie Wood's Ark Invest Offloads Uipath, Prime Medicine, And Repare Therapeutics

For retirees like Paula, 68, from New Jersey, the recent market plunge brought more than just numbers on a screen — it reignited old fears about outliving savings. "I'm just kind of stunned, and with so much money in the market, we just sort of have to hope we have enough time to recover," Paula told <a href="https://www.nbcnews.com/business/business-news/retirees-stunned-market-turmoil-tariffs-shrinks-401ks-rcna199753">NBC News</a>. Like many Americans who rely on 401(k) investments for <a href="https://www.benzinga.com/personal-finance/25/02/43895999/making-over-100000-a-year-heres-how-big-your-retirement-nest-egg-should-be-in-your-40s-50s-and-60s-if-you-want-to-retire-rich">retirement income</a>, she's now grappling with uncertainty about what lies ahead.
Last week saw U.S. stock markets tumble in reaction to sweeping new tariffs introduced by President Donald Trump. On Friday, the S&amp;P 500 dropped 6%, Nasdaq sank 5.8%, and the Dow lost over 2,200 points — marking one of the steepest declines since the pandemic crash in 2020. Combined with Thursday's losses, the market saw its largest two-day drop in history, with $6.6 trillion in value wiped out.&nbsp;
Don't Miss:
<ul>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
</ul>
<h2 class="wp-block-heading">&#8216;I Can't Stay Retired If This Continues&#8217;</h2>
Victor Fettes, 54, retired a week before the downturn. He told NBC News he lost $58,000 in just two days. "If that continues, I can't stay retired," he said. For those like Fettes, the timing couldn't be worse. <a href="https://www.benzinga.com/personal-finance/25/03/44348164/why-millions-of-americans-are-tapping-their-401k-savings-early">Retirement plans</a> that felt solid just days earlier are now under review.
Financial planner Brian Duffy told <a href="https://www.youtube.com/watch?v=WHt-hmrMg4A">KOMO-TV News</a> in Seattle that emotional reactions are common when markets dip — especially for those close to retirement. "Generally, those who are most emotional are unsure if they are prepped for retirement," he said. "Do not make long-term decisions on short-term news."
<h2 class="wp-block-heading">The Impact of Tariffs on Your 401(k)</h2>
The value of a 401(k) is closely tied to the <a href="https://www.benzinga.com/general/market-summary/25/04/44660779/sp-500-dow-jones-on-course-to-mimic-rare-consecutive-losses-not-seen-since-the-great-depression-whats-driving-the-fear">performance of the stock market</a>. And when the market drops suddenly, so do retirement account balances. Treasury Secretary Scott Bessent told NBC's "Meet the Press" on Sunday that, "Americans who want to retire right now, Americans who have put away for years in their savings accounts, I think they don&#8217;t look at the day-to-day fluctuations of what&#8217;s happening. And you know, in fact, most Americans don&#8217;t have everything in the market."
Trending: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.55 per share now</a>.
Bessent added that 401(k) plans often include a mix of stocks and bonds, like the popular "60/40" allocation — 60% stocks and 40% bonds.&nbsp;
While some in Washington suggest the downturn is temporary and that long-term investors shouldn't worry, many retirees don't have decades left to wait for a recovery.&nbsp;
<h2 class="wp-block-heading">Reevaluating Plans and Spending</h2>
Some Americans are hitting pause on their spending plans. Paula told NBC News that she and her partner are holding off on home renovations. Others are concerned about the impact on property values, particularly if they plan to sell. Mark Johnson, a 42-year veteran lobbyist from Washington, said the market turbulence made him question whether he should delay his upcoming retirement.
"What will this do to the value of my home which I plan to put on the market next month?" he asked KOMO News. Johnson had mapped out a post-retirement road trip in his RV to visit all 50 state capitals — but now wonders if he'll need to push back those plans.
See Also: It&#8217;s no wonder Jeff Bezos holds over $250 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
<h2 class="wp-block-heading">Expert Advice: Don't Panic, Rebalance Instead</h2>
Brad Clark, CEO of Solomon Financial, and other financial experts say the most important move right now is not to panic. Instead, this could be a good time to revisit your portfolio strategy.
"If you're near retirement, consider rebalancing — don't just go to cash," Clark told Time magazine. The common mantra of "sell high, buy low" still applies, but it's important to consult a financial advisor before making major changes.
Duffy said something similar, emphasizing that while recessions can feel long, they typically last 12 to 14 months. In contrast, bull markets can stretch out over several years. Keeping a long-term perspective is key — even if retirement is just around the corner.
For retirees and those nearing the milestone, the recent market volatility has created a wave of <a href="https://www.benzinga.com/personal-finance/25/03/44494260/dave-ramsey-reveals-how-to-rebound-from-financial-setbacks-if-youre-over-40-and-feeling-behind-its-not-too-late-but-youd-better-get-serious">financial unease</a>. Some are adjusting their plans, others are holding steady and hoping the market rebounds.
Read Next:
<ul>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
</ul>

Personal Finance

'We Just Have To Hope We Have Enough Time To Recover': Retirees Reeling After Market Drops Hit Their Nest Eggs

<ul>
<li>CNN reports that casual dining chains are in crisis, as evidenced by a 0.9% drop in sales over 2024</li>
<li>One contributing factor to the decline is rising prices, which have gone up by 34% over the last five years</li>
<li>Meanwhile, fast-casual restaurants have seen a 0.6% increase in sales, and fast food restaurants have seen a 1% increase in sales</li>
</ul>
Casual dining chains, a staple of the American restaurant industry, are facing a crisis, according to <a href="https://www.cnn.com/2025/04/04/business/hooters-red-lobster-tgi-fridays/index.html">CNN</a>. Four well-known establishments—TGI Fridays, Red Lobster, Hooters and Buca di Beppo— have iled for bankruptcy in the last few months. And several others, like Applebee's, Denny's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DENN#NASDAQ">DENN</a>), Outback Steakhouse, Bonefish Grill, Red Robin Gourmet Burger.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RRGB#NASDAQ">RRGB</a>), and Cracker Barrel Old Country Store Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBRL#NASDAQ">CBRL</a>), have seen a sharp drop in sales.&nbsp;
This downturn, CNN reports, is due to a number of factors, including hiking prices, shrinking incomes, and general mismanagement.
Don't Miss:
<ul>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>
Chains like Red Robin and TGI Fridays have long been favorites among lower and middle-income families who want a sit-down dinner without a several-hundred-dollar price tag. But as disposable incomes shrink and the threat of a recession increases, CNN says, these diners find themselves less willing to spring for a full meal out. Instead, they're opting to cook at home or visit fast food and fast casual chains like McDonald&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) and Chipotle Mexican Grill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>).&nbsp;
Data from the <a href="https://fred.stlouisfed.org/series/CUUR0000SEFV">US Bureau of Labor Statistics</a> also shows that restaurant prices have increased 34% since 2019, outpacing the overall growth of inflation. This has undoubtedly played a role in the 0.9% drop in sales at casual dining chains in 2024, that CNN reports, as well as the 0.6% and 1% increases at fast casual and fast food chains, respectively, where prices are already more affordable.
Trending: Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a>
But shrinking incomes and rising prices aren't the only reasons these dining institutions are struggling. Strategy mistakes and a reluctance to invest in location and service updates have also marred the chains' once-bright futures. For example, Hooters' racy atmosphere and reputation have become less appealing to diners over the few years, contributing to decreased sales. One of its prospective buyers recently told <a href="https://www.bloomberg.com/news/features/2025-03-27/hooters-bankruptcy-founders-to-welcome-families-end-bikini-nights?embedded-checkout=true">Bloomberg</a> it intends to give the establishment a family-friendly makeover. Only time will tell if the revamp will be enough or too little, too late.&nbsp;
Clarence Otis Jr., a former CEO of Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>), told CNN the struggling chains "got dated in terms of their menu offering, the look and feel of the restaurants, and how they reach consumers."&nbsp;
See Also: It&#8217;s no wonder Jeff Bezos holds over $250 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
While many chain restaurants are struggling, a few have managed to find the right recipe. Chili's, Olive Garden, and Texas Roadhouse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXRH#NASDAQ">TXRH</a>) are all seeing rising profits, thanks to their investments in labor and facilities and their dedication to keeping prices low, according to CNN.&nbsp;
Chili's, CNN says, has invested $400 million into their restaurants, simplifying the menu, adding more staff, and renovating existing locations. As a result, it's gone viral on social media apps like TikTok and has increased sales by 31% over the last quarter, its third consecutive quarter of double-digit sales growth.&nbsp;
"There's a widening gap between winners and losers in the casual dining category," and "brands that are investing in labor and the quality of guest experience are winning," Raymond James analyst Brian Voccaro told CNN.&nbsp;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
<li><a href="https://www.benzinga.com/money/arrived-private-credit-fund">Bezos' Favorite Real Estate Platform Launches A Way To Ride The Ongoing Private Credit Boom</a></li>
</ul>

CBRL

DENN

RRGB

TXRH

The End Of Casual Dining? Chain Restaurants Shutter By The Hundreds As Prices Increase By 34%

WIMI

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

PIIIW

PIII

South Korean AI hardware startup FuriosaAI has made waves in the global semiconductor industry after reportedly turning down an $800 million acquisition offer from Meta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>).
The decision shows the startup's ambition to remain independent and compete directly in the rapidly evolving <a href="https://www.benzinga.com/markets/emerging-markets/25/03/44229408/alibaba-unveils-new-ai-chip-to-power-chinas-open-source-tech-push-challenge-us-chip-gian">AI chip</a> market dominated by NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and increasingly encroached on by tech giants like Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>, GOOG)) and Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>).
Don't Miss:
<ul>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.55 per share now</a>.</li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a></li>
</ul>
<h2 class="wp-block-heading">Meta's $800 Million Power Play Rejected</h2>
Meta initially called FuriosaAI after months of evaluating potential acquisition targets earlier this year. While Meta&#8217;s offer was around $300 million more than FuriosaAI's estimated market value, negotiations collapsed over differences of opinion about the company's future direction and post-acquisition structure, according to a report by<a href="https://www.mk.co.kr/news/it/11271852"> Maeil Business Newspaper.</a>
&#8220;Since October of last year, Meta had been looking at several AI semiconductor companies in the U.S. and Israel, and finally made FuriosaAI a viable acquisition target and negotiated it since the beginning of the year," an insider reportedly told <a href="https://www.mk.co.kr/en/it/11271852">Maeil Business Newspaper</a>.&nbsp;
<h2 class="wp-block-heading">Inside South Korea's AI Chip Trailblazer</h2>
FuriosaAI, founded in 2017 by CEO June Paik, specializes in designing AI inference chips for high-performance applications as a power-efficient alternative to power-hungry GPUs. The company has about 140 employees, with more than 90% of them working in the development department. The team also includes veterans from Qualcomm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>), Samsung, and <a href="https://www.benzinga.com/25/04/44685818/nvidia-and-google-bet-big-on-quantum-ai-with-150m-investment-in-sandboxaq-raising-series-e-round-to-450-million">Google</a>.
Trending: Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a>
The startup's main product, RNGD (pronounced &#8220;Renegade&#8221;), is already getting serious hardware buzz. Launched at Hot Chips 2024, the RNGD chip is built on TSMC&#8217;s 5nm process and features dual HBM3 memory, achieving roughly twice the efficiency of traditional GPUs at just one-fourth of the power. In a world where energy-hungry AI models are growing fast, that's a pitch with global reach.
FuriosaAI has already found some notable partners, and production of RNGD is anticipated to start in the latter part of this year. According to <a href="https://www.mk.co.kr/news/it/11271852">Maeil Business Newspaper</a>, LG AI Research and Saudi Aramco are two of the companies that have signed up to test RNGD's capabilities.
FuriosaAI has raised about $52 million in funding by now, allowing it to develop the exceptional chips and laying the groundwork in place for mass production. While this figure is nothing compared to the tens of billions raised by some of the Silicon Valley dynamos, FuriosaAI&#8217;s recent moves have cemented its place on the map.
See Also: <a href="https://www.benzinga.com/money/vatom-adv">Invest in the Future of Digital Engagement. Own a Piece of the $100 Billion Metaverse Today for Just $500.</a>
<h2 class="wp-block-heading">Independent in a Chip War Era</h2>
The startup's determination to remain independent could signal bigger changes in the AI hardware ecosystem. Like the other hyperscalers, Meta is trying to reduce dependence on Nvidia's dominant chips by building or buying alternative solutions. But with specialized AI inference hardware in rising demand, startups such as FuriosaAI are increasingly unwilling to give up autonomy since they&#8217;re powered by next-generation innovation and deep technical know-how.
&#8220;Nvidia's dominance cannot last forever. There is a strong push to establish an alternative semiconductor ecosystem," CEO Paik said in an interview with <a href="https://www.kedglobal.com/mergers-acquisitions/newsView/ked202502120005">The Korea Economic Daily</a> in October. &#8220;Nvidia&#8217;s AI accelerators such as the H100 graphic processing units, sought after by companies, are in short supply and too expensive.&#8221;
FuriosaAI's decision to remain solo could turn out to be prescient. While Meta and other players are scrambling to build out vertically integrated AI stacks, the startup is going its own way, potentially redefining what it means to be a leader in AI hardware post-GPU.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/how-a-10k-bet-on-health-care-originals-could-have-skyrocketed-your-portfolio">With Shares Starting at Just $1.52, This Could be Your Chance to Invest in the Future of Healthcare.</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>

GOOGL

MSFT

NVDA

QCOM

FuriosaAI Turns Down Meta's $800M Bid To Go Rogue With RNGD, As AI Chip War Between Nvidia, Google, And Meta Heats Up

For many older Americans, <a href="https://www.benzinga.com/government/regulations/25/04/44678599/millions-of-americans-panic-after-receiving-erroneous-social-security-suspension-notices-due-to-system-glitch-report">Social Security</a> is more than just a monthly benefit — it's a financial lifeline. But recent government changes and comments from political leaders are making some seniors feel uneasy about the future of the program.
<h2 class="wp-block-heading">Concerns Sparked by Government Reorganization</h2>
At the center of this growing anxiety is a newly formed federal agency: the Department of Government Efficiency. Created through an executive order under the <a href="https://www.benzinga.com/personal-finance/25/04/44697671/trump-administrations-push-to-access-social-security-data-faces-major-setback-as-court-dismisses-appeal">Trump administration</a>, DOGE has been tasked with modernizing government systems and rooting out inefficiency and fraud. But in doing so, it has made waves by cutting thousands of federal jobs and reorganizing how certain agencies function — including the Social Security Administration, which serves nearly 73 million Americans each month.
Don't Miss:
<ul>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
</ul>
According to <a href="https://edition.cnn.com/2025/04/04/politics/video/trump-social-security-doge-digvid">CNN</a>, DOGE's overhaul of the SSA has left many seniors, especially those relying solely on benefits, feeling uncertain. At a senior center in Rockland County, New York, CNN&nbsp; spoke with seniors who expressed their fear that changes could lead to interruptions in their checks.
"I need Social Security — I can't manage without it," Deanna Nichols told CNN. "When I hear one of our politicians say ‘we&#8217;re not gonna touch medicare, we&#8217;re not gonna touch medicaid or social security,' I don't believe them."
<h2 class="wp-block-heading">Reactions to Leadership Comments</h2>
Although there have been no interruptions to benefits so far, some comments from officials have only added fuel to the fire. Commerce Secretary <a href="https://www.benzinga.com/personal-finance/25/03/44495568/those-who-scream-are-the-ones-stealing-commerce-secretary-says-only-fraudsters-will-complain-about-missed-social-security-checks">Howard Lutnick</a> recently made waves during an appearance on the "All-In Podcast."&nbsp;
Trending: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.55 per share now</a>.
"Let's say Social Security didn't send out their checks this month," he said. "My mother-in-law, who's 94, she wouldn't call and complain. She just wouldn&#8217;t. She&#8217;d think something got messed up, and she&#8217;ll get it next month. A fraudster always makes the loudest noise, screaming, yelling, and complaining."
That statement didn't sit well with many of the seniors who heard it. Milagros Velazquez, laughed and responded, "I'm a fraud. I'm a fraud cause I want what's due to me." Michael Gioeni, pointed out that many retirees live month to month and can't afford any delays.
<h2 class="wp-block-heading">Is There Real Risk to Social Security Benefits?</h2>
So far, no actual benefit cuts have taken place, and the Trump administration has stated it does not intend to reduce Social Security. However, The Senior Citizens League, or TSCL, warns that DOGE's sweeping access to federal data systems does raise valid questions.&nbsp;
TSCL Chairman Edward Cates <a href="https://seniorsleague.org/should-you-be-worried-about-doge-and-social-security/">said</a> that DOGE, though aimed at increasing efficiency, should not have direct access to individuals' personal Social Security data without clear, legal justification.
While DOGE is not authorized to delete benefits or directly alter Social Security accounts, seniors are encouraged to stay informed and cautious. Errors or system changes — especially in a brand-new agency — can still cause problems, even unintentionally.
See Also: It&#8217;s no wonder Jeff Bezos holds over $250 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
<h2 class="wp-block-heading">What Seniors Can Do to Stay Protected</h2>
If you're concerned about changes to Social Security or the security of your personal data, TSCL recommends a few important steps:
<ol>
<li>Know your rights under privacy laws, such as the <a href="https://bja.ojp.gov/program/it/privacy-civil-liberties/authorities/statutes/1279#:~:text=The%20Privacy%20Act%20%E2%80%9Cprotects%20certain,%2C%20social%20security%20number)%E2%80%A6.">Privacy Act of 1974</a>.</li>
<li>Monitor your benefit statements and report anything unusual.</li>
<li>Use official websites when checking on benefits or contacting agencies.</li>
<li>Enable strong passwords and two-factor authentication on any online accounts.</li>
<li>Reach out to trusted individuals for help navigating government services.</li>
</ol>
<h2 class="wp-block-heading">A Need for Reassurance</h2>
Seniors who've paid into Social Security for decades want to know that what they've earned is safe. As Catherine Baris, another Rockland County senior, told CNN: "We worked for that money&#8230; You want to feel that you can pay your bills, that you can eat. These are our golden years. I don't see it."
For now, while <a href="https://www.benzinga.com/personal-finance/25/04/44682363/aprils-social-security-changes-how-new-rules-could-affect-your-check">Social Security checks</a> are still arriving on time, the broader conversation about how federal efficiency efforts may impact essential programs is far from over.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>

'When I Hear Our Politicians Say We're Not Gonna Touch Social Security, I Don't Believe Them' – Seniors Are Worried About DOGE Changes

During the last three months, 6 analysts shared their evaluations of ANI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $87.5, a high estimate of $94.00, and a low estimate of $80.00. This current average has decreased by 2.23% from the previous average price target of $89.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1744408856_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of ANI Pharmaceuticals by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Vamil Divan &#x7C;Guggenheim &#x7C;Maintains &#x7C;Buy &#x7C; $86.00&#x7C;$86.00 &#x7C; 
&#x7C;Oren Livnat &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $94.00&#x7C;$94.00 &#x7C; 
&#x7C;Glen Santangelo &#x7C;Jefferies &#x7C;Announces &#x7C;Buy &#x7C; $80.00&#x7C;- &#x7C; 
&#x7C;Ekaterina Knyazkova &#x7C;JP Morgan &#x7C;Announces &#x7C;Overweight &#x7C; $85.00&#x7C;- &#x7C; 
&#x7C;Vamil Divan &#x7C;Guggenheim &#x7C;Raises &#x7C;Buy &#x7C; $86.00&#x7C;$84.00 &#x7C; 
&#x7C;Oren Livnat &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $94.00&#x7C;$94.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to ANI Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of ANI Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for ANI Pharmaceuticals's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of ANI Pharmaceuticals's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ANIP/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on ANI Pharmaceuticals analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering ANI Pharmaceuticals: A Closer Look</h2>
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
<h3>ANI Pharmaceuticals's Economic Impact: An Analysis</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: ANI Pharmaceuticals's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 44.75%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: ANI Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of -5.61%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -2.64%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -0.83%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 1.55, ANI Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

ANIP

Deep Dive Into ANI Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)

During the last three months, 4 analysts shared their evaluations of Healthpeak Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>), revealing diverse outlooks from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $23.75, a high estimate of $24.00, and a low estimate of $23.00. This current average has decreased by 5.0% from the previous average price target of $25.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1744408848_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A clear picture of Healthpeak Properties's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Richard Anderson &#x7C;Wedbush &#x7C;Maintains &#x7C;Outperform &#x7C; $24.00&#x7C;$24.00 &#x7C; 
&#x7C;Nicholas Yulico &#x7C;Scotiabank &#x7C;Lowers &#x7C;Sector Outperform&#x7C; $23.00&#x7C;$24.00 &#x7C; 
&#x7C;Richard Anderson &#x7C;Wedbush &#x7C;Lowers &#x7C;Outperform &#x7C; $24.00&#x7C;$27.00 &#x7C; 
&#x7C;Amanda Sweitzer &#x7C;Baird &#x7C;Lowers &#x7C;Outperform &#x7C; $24.00&#x7C;$25.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Healthpeak Properties. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Healthpeak Properties compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Healthpeak Properties's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Healthpeak Properties's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/DOC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Healthpeak Properties analyst ratings.</a>
<h2>Discovering Healthpeak Properties: A Closer Look</h2>
Healthpeak owns a diversified healthcare portfolio of approximately 697 in-place properties spread across mainly medical office and life science assets, plus a handful of senior housing, hospital, and skilled nursing/post-acute care assets, as well.
<h3>Healthpeak Properties: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Positive Revenue Trend: Examining Healthpeak Properties's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 26.07% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 0.63%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Healthpeak Properties's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 0.05%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Healthpeak Properties's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.02%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Healthpeak Properties's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.07.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Healthpeak Properties Through 4 Analysts

Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) underwent analysis by 14 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">8</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $66.64, along with a high estimate of $90.00 and a low estimate of $50.00. This current average represents a 13.53% decrease from the previous average price target of $77.07. 
<img src="https://www.benzinga.com/files/images/story/2025/1744408840_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Microchip Technology among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Christopher Danely &#x7C;Citigroup &#x7C;Lowers &#x7C;Buy &#x7C; $50.00&#x7C;$65.00 &#x7C; 
&#x7C;Mark Lipacis &#x7C;Evercore ISI Group &#x7C;Raises &#x7C;Outperform &#x7C; $71.00&#x7C;$65.00 &#x7C; 
&#x7C;Vijay Rakesh &#x7C;Mizuho &#x7C;Raises &#x7C;Outperform &#x7C; $68.00&#x7C;$58.00 &#x7C; 
&#x7C;Kevin Cassidy &#x7C;Rosenblatt &#x7C;Maintains &#x7C;Buy &#x7C; $70.00&#x7C;$70.00 &#x7C; 
&#x7C;Quinn Bolton &#x7C;Needham &#x7C;Raises &#x7C;Buy &#x7C; $66.00&#x7C;$60.00 &#x7C; 
&#x7C;Craig Ellis &#x7C;B. Riley Securities &#x7C;Lowers &#x7C;Buy &#x7C; $75.00&#x7C;$85.00 &#x7C; 
&#x7C;Melissa Fairbanks &#x7C;Raymond James &#x7C;Lowers &#x7C;Strong Buy &#x7C; $60.00&#x7C;$95.00 &#x7C; 
&#x7C;John Vinh &#x7C;Keybanc &#x7C;Lowers &#x7C;Overweight &#x7C; $60.00&#x7C;$70.00 &#x7C; 
&#x7C;Harsh Kumar &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $65.00&#x7C;$85.00 &#x7C; 
&#x7C;Quinn Bolton &#x7C;Needham &#x7C;Lowers &#x7C;Buy &#x7C; $60.00&#x7C;$85.00 &#x7C; 
&#x7C;Hans Mosesmann &#x7C;Rosenblatt &#x7C;Lowers &#x7C;Buy &#x7C; $70.00&#x7C;$90.00 &#x7C; 
&#x7C;Hans Mosesmann &#x7C;Rosenblatt &#x7C;Maintains &#x7C;Buy &#x7C; $90.00&#x7C;$90.00 &#x7C; 
&#x7C;Joseph Moore &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $58.00&#x7C;$71.00 &#x7C; 
&#x7C;John Vinh &#x7C;Keybanc &#x7C;Lowers &#x7C;Overweight &#x7C; $70.00&#x7C;$90.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Microchip Technology. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Microchip Technology compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Microchip Technology's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Microchip Technology's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MCHP/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Microchip Technology analyst ratings.</a>
<h2>Unveiling the Story Behind Microchip Technology</h2>
Microchip Technology became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
<h3>Microchip Technology's Financial Performance</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Decline in Revenue: Over the 3M period, Microchip Technology faced challenges, resulting in a decline of approximately -41.89% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Microchip Technology's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -5.22%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -0.87%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -0.34%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Microchip Technology's debt-to-equity ratio stands notably higher than the industry average, reaching 1.12. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MCHP

Beyond The Numbers: 14 Analysts Discuss Microchip Technology Stock

Analysts' ratings for PACCAR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCAR#NASDAQ">PCAR</a>) over the last quarter vary from bullish to bearish, as provided by 14 analysts.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $111.54, with a high estimate of $132.00 and a low estimate of $78.00. Highlighting a 5.23% decrease, the current average has fallen from the previous average price target of $117.69. 
<img src="https://www.benzinga.com/files/images/story/2025/1744408833_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive PACCAR. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Tami Zakaria &#x7C;JP Morgan &#x7C;Lowers &#x7C;Overweight &#x7C; $105.00&#x7C;$121.00 &#x7C; 
&#x7C;Kyle Menges &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $95.00&#x7C;$105.00 &#x7C; 
&#x7C;Jamie Cook &#x7C;Truist Securities &#x7C;Lowers &#x7C;Hold &#x7C; $104.00&#x7C;$113.00 &#x7C; 
&#x7C;Steven Fisher &#x7C;UBS &#x7C;Lowers &#x7C;Sell &#x7C; $78.00&#x7C;$108.00 &#x7C; 
&#x7C;Kyle Menges &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $105.00&#x7C;$112.00 &#x7C; 
&#x7C;Tami Zakaria &#x7C;JP Morgan &#x7C;Lowers &#x7C;Overweight &#x7C; $121.00&#x7C;$132.00 &#x7C; 
&#x7C;Steven Fisher &#x7C;UBS &#x7C;Announces &#x7C;Neutral &#x7C; $108.00&#x7C;- &#x7C; 
&#x7C;David Raso &#x7C;Evercore ISI Group &#x7C;Lowers &#x7C;Outperform &#x7C; $127.00&#x7C;$129.00 &#x7C; 
&#x7C;Tami Zakaria &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $132.00&#x7C;$125.00 &#x7C; 
&#x7C;Jamie Cook &#x7C;Truist Securities &#x7C;Raises &#x7C;Hold &#x7C; $113.00&#x7C;$112.00 &#x7C; 
&#x7C;Jamie Cook &#x7C;Truist Securities &#x7C;Raises &#x7C;Hold &#x7C; $112.00&#x7C;$110.00 &#x7C; 
&#x7C;Kyle Menges &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $115.00&#x7C;$125.00 &#x7C; 
&#x7C;Ross Gilardi &#x7C;B of A Securities &#x7C;Raises &#x7C;Buy &#x7C; $121.50&#x7C;$116.00 &#x7C; 
&#x7C;Tami Zakaria &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $125.00&#x7C;$122.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to PACCAR. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of PACCAR compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for PACCAR's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into PACCAR's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PCAR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on PACCAR analyst ratings.</a>
<h2>Unveiling the Story Behind PACCAR</h2>
Paccar is a leading manufacturer of medium- and heavy-duty trucks under the premium brands Kenworth and Peterbilt (primarily sold in the NAFTA region and Australia), and DAF trucks (sold in Europe and South America). The company's trucks are sold through more than 2,300 independent dealers globally. Paccar Financial Services provides retail and wholesale financing for customers and dealers, respectively. The company commands roughly 30% of the Class 8 market share in North America and 17% of the heavy-duty market share in Europe.
<h3>Key Indicators: PACCAR's Financial Health</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Negative Revenue Trend: Examining PACCAR's financials over 3M reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -12.88% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 11.03%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): PACCAR's ROE excels beyond industry benchmarks, reaching 4.82%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): PACCAR's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.01% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: PACCAR's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.91.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PCAR

The Analyst Verdict: PACCAR In The Eyes Of 14 Experts

During the last three months, 4 analysts shared their evaluations of Federated Hermes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHI#NYSE">FHI</a>), revealing diverse outlooks from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $39.5, with a high estimate of $41.00 and a low estimate of $38.00. Experiencing a 4.24% decline, the current average is now lower than the previous average price target of $41.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1744408825_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Federated Hermes. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;John Dunn &#x7C;Evercore ISI Group &#x7C;Lowers &#x7C;Outperform &#x7C; $38.00&#x7C;$42.00 &#x7C; 
&#x7C;Kenneth Worthington &#x7C;JP Morgan &#x7C;Lowers &#x7C;Underweight &#x7C; $41.00&#x7C;$42.00 &#x7C; 
&#x7C;Adam Beatty &#x7C;UBS &#x7C;Raises &#x7C;Neutral &#x7C; $40.00&#x7C;$39.00 &#x7C; 
&#x7C;Kenneth Lee &#x7C;RBC Capital &#x7C;Lowers &#x7C;Sector Perform &#x7C; $39.00&#x7C;$42.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Federated Hermes. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Federated Hermes compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Federated Hermes's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Federated Hermes's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/FHI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Federated Hermes analyst ratings.</a>
<h2>All You Need to Know About Federated Hermes</h2>
Federated Hermes provides asset-management services for institutional and individual investors. The firm had $800 billion in managed assets at the end of September 2024, composed of equity (10%), multi-asset (less than 1%), fixed-income (12%), alternative (3%), and money market (74%) funds. The firm's cash-management operations are expected to generate around 51% of Federated's revenue this year, compared with 29%, 12%, and 7%, respectively, for the equity, fixed-income, and alternatives/multi-asset operations. The company's products are distributed via trust banks, wealth managers, and retail broker/dealers (65% of AUM), institutional investors (26%), and international clients (9%).
<h3>Federated Hermes: A Financial Overview</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Federated Hermes's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 8.48%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.
Net Margin: Federated Hermes's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 19.09%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Federated Hermes's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 7.44% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Federated Hermes's ROA stands out, surpassing industry averages. With an impressive ROA of 3.93%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.42, Federated Hermes adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Federated Hermes's Future

In the current market session, Tidewater Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDW#NYSE">TDW</a>) price is at $35.34, after a 4.93% spike. However, over the past month, the stock decreased by 12.55%, and in the past year, by 62.26%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1744408820_0.png" alt="Past Year Chart" />

<h3>Tidewater P/E Compared to Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 16.87 in the Energy Equipment &amp; Services industry, Tidewater Inc. has a lower P/E ratio of 9.91. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1744408820_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Price Over Earnings Overview: Tidewater

Ratings for Qualcomm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Qualcomm and provided 12-month price targets. The average target is $188.62, accompanied by a high estimate of $250.00 and a low estimate of $145.00. A 7.65% drop is evident in the current average compared to the previous average price target of $204.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1744408817_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Qualcomm among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Christopher Danely &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $145.00&#x7C;$185.00 &#x7C; 
&#x7C;Joshua Buchalter &#x7C;TD Cowen &#x7C;Lowers &#x7C;Buy &#x7C; $160.00&#x7C;$195.00 &#x7C; 
&#x7C;Cody Acree &#x7C;Benchmark &#x7C;Maintains &#x7C;Buy &#x7C; $240.00&#x7C;$240.00 &#x7C; 
&#x7C;Mark Lipacis &#x7C;Evercore ISI Group &#x7C;Lowers &#x7C;In-Line &#x7C; $179.00&#x7C;$199.00 &#x7C; 
&#x7C;Matthew Prisco &#x7C;Cantor Fitzgerald &#x7C;Maintains &#x7C;Neutral &#x7C; $160.00&#x7C;$160.00 &#x7C; 
&#x7C;Harsh Kumar &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $190.00&#x7C;$205.00 &#x7C; 
&#x7C;Kevin Cassidy &#x7C;Rosenblatt &#x7C;Maintains &#x7C;Buy &#x7C; $250.00&#x7C;$250.00 &#x7C; 
&#x7C;Tom O'Malley &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $185.00&#x7C;$200.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Qualcomm. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Qualcomm compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Qualcomm's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Qualcomm's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/QCOM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Qualcomm analyst ratings.</a>
<h2>Get to Know Qualcomm Better</h2>
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G, 4G, and 5G networks. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones, as well as chips into automotive and Internet of Things markets.
<h3>Financial Milestones: Qualcomm's Journey</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3M period, Qualcomm showcased positive performance, achieving a revenue growth rate of 17.45% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Qualcomm's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 27.25% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Qualcomm's ROE excels beyond industry benchmarks, reaching 11.97%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Qualcomm's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.74% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Qualcomm's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.54, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Qualcomm: Insights From 8 Analyst Reviews

Scotiabank analyst Paul Cheng maintains Exxon Mobil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) with a Sector Outperform and lowers the price target from $140 to $115.

Price Target

Scotiabank Maintains Sector Outperform on Exxon Mobil, Lowers Price Target to $115

Scotiabank analyst Paul Cheng maintains Valero Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLO#NYSE">VLO</a>) with a Sector Outperform and lowers the price target from $156 to $136.

Scotiabank Maintains Sector Outperform on Valero Energy, Lowers Price Target to $136

Scotiabank analyst Paul Cheng maintains TotalEnergies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTE#NYSE">TTE</a>) with a Sector Perform and lowers the price target from $65 to $60.

Comments

Direxion Daily S&P 500 Bear 3X

Notizie

Ultime notizie per Direxion Daily S&P 500 Bear 3X (ARCA:SPXS)

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO